David Kan
Impact in
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
-
- Chronic Myeloid Leukemia Treatments 6
-
- Endoplasmic Reticulum Stress and Disease 4
- Co-authors
- Shang‐Fan Yu (2 shared papers)Stephen Castaneda (8 shared papers)Chingwei V. Lee (1 shared paper)Christian Wiesmann (1 shared paper)Franklin V. Peale Jr. (1 shared paper)Wenyan Man (1 shared paper)Jenny Boström (1 shared paper)Karen L. Billeci (1 shared paper)
- Journals
- Cancer Research (5 papers)Blood (4 papers)Clinical Cancer Research (3 papers)Journal of Medicinal Chemistry (2 papers)Cancer Chemotherapy and Pharmacology (1 paper)
- Partner nations
- United StatesNetherlandsFrance
In The Last Decade
David Kan
27 papers receiving 2.3k citations
David Kan's Hit Papers
Peers
Comparison fields: 5 of 81
- Hematology 484
- Radiology, Nuclear Medicine and Imaging 317
- Oncology 282
- Cell Biology 159
- Molecular Biology 631
Countries citing papers authored by David Kan
This map shows the geographic impact of David Kan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kan more than expected).
Fields of papers citing papers by David Kan
This network shows the impact of papers produced by David Kan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kan. The network helps show where David Kan may publish in the future.
Co-authors
The 25 scholars most cited alongside David Kan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 28 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays Hit paper breakdown → | 2004 | 1141 |
| 2 | 2009 | 298 | |
| 3 | Antibody targeting of E3 ubiquitin ligases for receptor degradation Hit paper breakdown → | 2022 | 196 |
| 4 | 2006 | 125 | |
| 5 | 2019 | 91 | |
| 6 | 2015 | 86 | |
| 7 | 2020 | 74 | |
| 8 | 2005 | 73 | |
| 9 | 2006 | 61 | |
| 10 | 2008 | 40 | |
| 11 | BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo | 2005 | 38 |
| 12 | 2013 | 33 | |
| 13 | 2016 | 29 | |
| 14 | 2022 | 26 | |
| 15 | 2005 | 23 | |
| 16 | 2005 | 21 | |
| 17 | 2022 | 20 | |
| 18 | 2019 | 18 | |
| 19 | 2005 | 17 | |
| 20 | 2004 | 10 |
About David Kan
David Kan is a scholar working on Hematology, Cell Biology, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 28 papers that have together received 2.5k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (6 papers), Endoplasmic Reticulum Stress and Disease (4 papers), Protein Kinase Regulation and GTPase Signaling (3 papers), Angiogenesis and VEGF in Cancer (3 papers), HER2/EGFR in Cancer Research (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Substance Abuse Treatment and Outcomes (2 papers). The work is most often cited by research in Hematology (484 citations), Radiology, Nuclear Medicine and Imaging (317 citations), Oncology (282 citations), Cell Biology (159 citations) and Molecular Biology (631 citations). David Kan has collaborated with scholars based in United States, Netherlands and France. Frequent co-authors include Shang‐Fan Yu, Stephen Castaneda, Chingwei V. Lee, Christian Wiesmann, Franklin V. Peale Jr., Wenyan Man, Jenny Boström, Karen L. Billeci, Germaine Fuh and B.A. Appleton. Their work appears in journals such as Cancer Research, Blood, Clinical Cancer Research, Journal of Medicinal Chemistry and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.